Market Highlights
Chorea is a nonrhythmic, rapid, non-suppressible involuntary
movement. Chorea is often worsened by anxiety, stress and subsides during
sleep. It is also found that most patients attempt to disguise chorea by a
purposeful activity. Sydenham’s chorea is the most common form of chorea in
childhood, whereas Huntington’s disease, and drug induced chorea found mostly
in adult onset cases.
A number of factor such as growing public awareness, and
technological advancements, rising prevalence of neurological disorders,
increasing awareness, improving regulatory framework, increasing government
assistance, increasing adoption rate, and rising funding and reimbursement
policies are propelling the growth of the global chorea market.
However, challenges in research and development,
side-effects of treatment, cost of treatment, the presence of misbranded and
spurious drugs and poor healthcare system in low and middle-income countries
may hamper the growth of the market.
It is estimated that the Chorea
Market is expected to grow at a CAGR 11.4% during the forecast period of
2017-2023.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/5220
Key Players
Some of key the players in the global chorea market are Teva
Pharmaceutical Industries Ltd., Valeant, Medtronic, Alnylam Pharmaceuticals,
Inc., Cyberonics, Inc., AmpliPhi Biosciences Corp, Ceregene Inc., Boston
Scientific Corporation, GlaxoSmithKline plc, Lundbeck, Prana Biotechnology
Limited, Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, SOM
Biotech, Raptor Pharmaceutical, Omeros, Ipsen, Pfizer, Palobiofarma, Aleva
Neurotherapeutics SA, and others.
Segmentation
The Global Chorea Market is segmented on the basis of type,
treatment, and distribution channels.
On the basis of the type, the market is classified as
Huntington’s disease, Rheumatic (Sydenham’s chorea), and Drug-induced chorea.
On the basis of the treatment, the market is classified as
medical care, and surgical care. The medical care is further segmented into
neuroleptics, dopamine-depleting agents, GABAergic drugs, coenzyme Q10,
intravenous immunoglobulin, and plasmapheresis. The sub segments neuroleptic
includes, typical neuroleptics, and atypical neuroleptics. The surgical care is
further segmented into deep brain stimulation, and cell transplantation.
On the basis of the distribution channel, the market is
segmented into hospitals, clinics, diagnostic centers, drug stores, pharmacies,
and others.
Regional Analysis
The Americas dominate the chorea market owing to the rising
awareness among people, and high healthcare expenditure. According to the
Centers for Disease Control and Prevention in 2015, the total health
expenditure in the United States was reported to be USD 3.2 trillion and
hospital care accounted for a share of 32.3%.
Europe holds the second position in the chorea market. It is
expected that the support provided by the government bodies for research &
development and improvement in reimbursement policies in the healthcare is
likely to drive the market of Europe region.
Asia Pacific is the fastest growing chorea market owing to a
huge patient pool and developing healthcare technology. Healthcare expenditure
is also improving in various Asia Pacific countries. According to the
Australian Institute of Health and Welfare in the years 2015-2016, the total
health expenditure was USD 170.4 billion, which is 3.6% higher than the
expenditure of 2014-2015.
The Middle East & Africa holds the lowest market due to
lack of technical knowledge and poor medical facilities.
Browse Full Report @ https://www.marketresearchfuture.com/reports/chorea-market-5220 .
About US:
Market Research Future (MRFR), enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The Wall